NCT04734418 is a NA clinical trial of Remifentanil in NIV Intolerance, sponsored by Shanghai Zhongshan Hospital.

Who is sponsoring NCT04734418?

NCT04734418 is sponsored by Shanghai Zhongshan Hospital.

What drugs are being tested in NCT04734418?

Interventions in NCT04734418: Remifentanil, Dexmedetomidine.

What condition does NCT04734418 study?

NCT04734418 studies NIV Intolerance.

Is NCT04734418 still recruiting?

NCT04734418 is currently status unknown. Last updated 16 March 2021.

Last reviewed 2021-03-16 · How we verify

NCT04734418

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Remifentanil and Dexmedetomidine in Patients With Noninvasive Mechanical Ventilation Intolerance

Status unknown NA Last updated 16 March 2021

What this trial tests

NA trial testing Remifentanil in NIV Intolerance in 178 participants. Status unknown.

Timeline

8 March 2021

Primary endpoint
31 January 2023

28 February 2023

Quick facts

Lead sponsor	Shanghai Zhongshan Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	178
Start date	8 March 2021
Primary completion	31 January 2023
Estimated completion	28 February 2023
Sites	1 location across China

Drugs / interventions tested

Remifentanil — full drug profile →
Dexmedetomidine (dexmedetomidine) — full drug profile →

Conditions studied

NIV Intolerance — all drugs for NIV Intolerance →

Sponsor

Shanghai Zhongshan Hospital

Who can join

Adults 18 to 75, any sex, with NIV Intolerance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Currently, NIV(Noninvasive ventilation ) is widely used in patients with hypoxemia and atelectasis after cardiac surgery.About 15% of patients have intolerance during NIV. The main manifestation is that the patient feels uncomfortable, often breaks away from the mask, and even gradually becomes agitated, which eventually leads to the failure of non-invasive ventilation.The patient's intubation rate is as high as 44%, and the mortality rate is 34%.There are many ways to prevent or treat NIV intolerance, of which the most used is to sedate the patient. This study aims to evaluate the effects of remifentanil and dexmedetomidine in the sedation of patients with intolerance to non-invasive mechanical ventilation after cardiac surgery, and to explore the optimal plan for sedation of patients with intolerant non-invasive mechanical ventilation after cardiac surgery.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Remifentanil versus Dexmedetomidine in Cardiac Surgery Patients with Noninvasive Ventilation Intolerance: Protocol for the REDNIVI Trial.
Luo MH, Hao GW, Liu K, Yin K, et al · · 2022 · cited 3× · PMID 35345251 · DOI 10.31083/j.rcm2303084
Remifentanil vs. dexmedetomidine for cardiac surgery patients with noninvasive ventilation intolerance: a multicenter randomized controlled trial.
Hao GW, Wu JQ, Yu SJ, Liu K, et al · · 2024 · cited 2× · PMID 39294818 · DOI 10.1186/s40560-024-00750-2
Postoperative glucocorticoids in patients with acute type A aortic dissection (GLAD): study protocol for a prospective, single-center, randomized controlled trial.
Deng YZ, Luo MH, Luo JC, Li JK, et al · · 2023 · cited 1× · PMID 37189085 · DOI 10.1186/s12871-023-02124-x

Verify or expand the search:

Other trials of Remifentanil

Trials testing the same drug.

NCT06564857 — Remifentanil Versus Rocuronium for Optimizing Video Laryngoscopy-assisted Tracheal Intubation · Phase 4 · recruiting
NCT07336628 — Propofol vs Remifentanil for Sedation in Gastroscopy · NA · active not recruiting
NCT07301970 — Population Pharmacokinetics of Remifentanil in Low-Weight Critically Ill Patients · recruiting
NCT07092384 — Effect of Remifentanil on Pruritus and Paresthesia of Fospropofol Disodium Anesthesia · NA · completed
NCT06958393 — Effect of Opioid-free Anaesthesia on Postoperative Delirium in Elderly Patients Undergoing Gastrointestinal Surgery · Phase 4 · not yet recruiting

Other Shanghai Zhongshan Hospital trials

Trials by the same sponsor.

NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04734418 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
Last refreshed: 16 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04734418.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing